Announcement on Subsidiary Company Obtaining Drug Registration Certificate
Release time:
2021-05-20
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Lin 2020-023
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Subsidiaries Obtaining Drug Registration Certificate
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assume individual and joint responsibility for the truthfulness, accuracy and completeness of its contents.
Important Content Note:
- Obtaining the Drug Registration Certificate of esomeprazole sodium for injection this time indicates that Jianfeng Pharmaceutical is qualified to produce and sell the drug, which will further enrich Jianfeng Pharmaceutical's product line and help enhance the competitiveness of the company's pharmaceutical business.
- Risk Warning: Because pharmaceutical products have the characteristics of high technology, high risk, and high added value, not only the pre-research and development of drugs, the period from approval to production is long, the investment is large, and there are many links, and the drug has obtained the registration The production and sales after the certificate are also easily affected by factors such as national policies and market environment. Investors are requested to pay attention to investment risks.
Recently, Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company"), a holding subsidiary of Zhejiang Jianfeng Group Co., Ltd. (hereinafter referred to as "the Company"), received the Drug Registration Certificate of esomeprazole sodium for injection (Certificate No.: 2020S00572) approved and issued by the State Drug Administration. The relevant information is hereby announced as follows: basic Information of
1. Drugs
Drug Name: Esomeprazole Sodium for Injection
Dosage Form: Injection
Specification: 40mg (calculated by C 17 H 19 N 3 O 3 S)
Application Items: drug Registration (Domestic Production)
Registration Classification: Original Chemical Drug Category 6
Applicant: Zhejiang Jianfeng Pharmaceutical Co., Ltd.
acceptance number: CYHS1301863 Zhejiang
Certificate No.: 2020S00572
Drug Registration Standard No.: YBH03162020
Drug Validity Period: 12 Months
Drug Approval Number: the validity period of the drug approval document number of the national drug standard H20203449
is until August 25, 2025
approval conclusion: according to the the People's Republic of China drug administration law and relevant regulations, after examination, this product meets the relevant requirements for drug registration, is approved for registration, and a drug registration certificate is issued. The production process, quality standards, instructions and labels shall be in accordance with the attached.
2. Drug Development and Related Conditions
This product is used to treat:
1. as an alternative therapy for GERD when oral therapy is not applicable.
2. Use in low-risk patients with acute gastric or duodenal ulcer bleeding for whom oral therapy is not applicable (gastroscopic Forrest grading IIc-III).
Esomeprazole sodium for injection has been listed in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition)" and classified as Class B; it is not included in the "National Essential Drugs List (2018 Edition)". At present, 30 enterprises, including AstraZeneca Pharmaceutical Co., Ltd., Zhengda Tianqing Pharmaceutical Group Co., Ltd., Qilu Pharmaceutical Co., Ltd., and Shandong Luoxin Pharmaceutical Group Co., Ltd., have been approved for listing in China. According to the data of the intranet, the domestic sales in 2019 (including urban and county-level public hospitals, community and township health centers) are about 3.317 billion yuan.
Peak Pharmaceutical submitted an application for registration of the drug to the State Food and Drug Administration on November 28, 2013 and was accepted. Up to now, the research and development investment of esomeprazole sodium for injection project of Jianfeng Pharmaceutical Co., Ltd. is about 14.9128 million yuan. The impact of
3. on the company and its risks suggest that
Jianfeng Pharmaceutical already has a corresponding production line. The acquisition of the Drug Registration Certificate of esomeprazole sodium for injection this time indicates that Jianfeng Pharmaceutical has the qualification to produce and sell the drug, which will further enrich the product line of Jianfeng Pharmaceutical and help to enhance the competitiveness of the company's pharmaceutical business. Due to the characteristics of high technology, high risk and high added value of pharmaceutical products, not only the period from the preliminary research and development, approval to production is long, the investment is large and there are many links, but also the production and sales of drugs after obtaining the registration certificate are easily affected by national policies, market environment and other factors. Please pay attention to the investment risk.
This is to announce
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
September 5, 2020
More information
Representatives of the 20th Congress preached the 20th Congress at the peak.
On the afternoon of November 11, a special lecture on the spirit of the Party's 20th Congress was held in the conference room of the Peak Building. Yang Xiayun, a representative of the 20th National Congress, walked into the peak and preached his understanding of the spirit of the 20th National Congress for Party members through personal experience.
2022
11-23
The group party committee organizes and learns the twenty spirits.
On the afternoon of October 28, the party Committee of the group organized all members to hold a special study meeting to earnestly study and understand the communique of the first plenary session of the 20th central Committee of the communist party of China and the revision of the party constitution. Jiang Xiaomeng, Secretary of the Party committee of the group, stressed at the study meeting that the 20th National Congress of the Communist Party of China has drawn a grand blueprint for building a socialist modern country in an all-round way, opened a new chapter in the era of national development, and pointed out the direction for the future development of enterprises. Party organizations at all levels of the group should pay full attention to and earnestly implement it, actively organize party members and cadres to learn the spirit of the spirit of the 20th National Congress, And to guide the future work practice.
2022
11-01
Spike Party Members and Cadres Watch the Opening Meeting of the 20th Congress
At 10 a.m. on October 16, the 20th National Congress of the Communist Party of China was solemnly opened in the Great Hall of the People in Beijing. Xi Jinping delivered a report to the Party's 20th National Congress on behalf of the 19th Central Committee. The group company attaches great importance to and carefully deploys, and organizes all party members and management backbones of the group headquarters and subsidiaries to watch the live broadcast of the opening meeting through the Internet, TV and other methods.
2022
10-23
Jiang Xiaomeng was hired as the "Shuanglong Escort" entrepreneurial mentor.
On September 16, Jiang Xiaomeng, Secretary of the Party committee and chairman of the group company, was employed as the entrepreneurial mentor of "Shuanglong escort" at the launching ceremony of the special action of "Shuanglong escort steady progress and quality improvement" held in Jinhua City and the promotion meeting of innovative products of key talent enterprises in Jinhua City.
2022
09-27
From August 18th to 19th, the 12th Congress of the Zhejiang Federation of Industry and Commerce was held in Hangzhou, and the 12th leadership of the Provincial Federation of Industry and Commerce was elected. Jiang Xiaomeng, Secretary of the Party Committee and Chairman of the Group, was re-elected as Vice President of Zhejiang Chamber of Commerce.
2022
09-01
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page